Movatterモバイル変換

[0]ホーム

Jump to content

SB-612,111

Edit links

From Wikipedia, the free encyclopedia

(Redirected fromSB-612111)

Chemical compound

Pharmaceutical compound

SB-612,111
Clinical data

Other names	SB-612,111
Identifiers
IUPAC name (5S,7S)-7-{[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl}-1-methyl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-ol
CAS Number	371980-98-2^N
PubChemCID	10047612
IUPHAR/BPS	1693
ChemSpider	8223175^N
ChEMBL	ChEMBL559569^N
CompTox Dashboard(EPA)	DTXSID301027159 DTXSID40610405, DTXSID301027159
Chemical and physical data
Formula	C₂₄H₂₉Cl₂NO
Molar mass	418.40 g·mol⁻¹
3D model (JSmol)	Interactive image Interactive image
SMILES CC1=CC=CC2=C1CC[C@@H](C[C@@H]2O)CN3CCC(CC3)C4=C(C=CC=C4Cl)Cl CC1=C2CC[C@@H](C[C@@H](C2=CC=C1)O)CN3CCC(CC3)C4=C(C=CC=C4Cl)Cl
InChI InChI=1S/C24H29Cl2NO/c1-16-4-2-5-20-19(16)9-8-17(14-23(20)28)15-27-12-10-18(11-13-27)24-21(25)6-3-7-22(24)26/h2-7,17-18,23,28H,8-15H2,1H3/t17-,23-/m0/s1^N Key:OHRDCQFCAWLDBP-SBUREZEXSA-N^N
^NY (what is this?) (verify)

SB-612,111 is anopioid receptor ligand which is a potent and selective antagonist for thenociceptin receptor (ORL-1), several times more potent than the older drug J-113,397.^[1] It does not haveanalgesic effects in its own right, but prevents the development ofhyperalgesia,^[2] and also showsantidepressant effects in animal studies.^[3]

References

[edit]

^Spagnolo B, Carrà G, Fantin M, Fischetti C, Hebbes C, McDonald J, et al. (June 2007). "Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies".The Journal of Pharmacology and Experimental Therapeutics.321 (3):961–7.doi:10.1124/jpet.106.116764.PMID 17329552.S2CID 17504101.
^Zaratin PF, Petrone G, Sbacchi M, Garnier M, Fossati C, Petrillo P, et al. (February 2004). "Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111)".The Journal of Pharmacology and Experimental Therapeutics.308 (2):454–61.doi:10.1124/jpet.103.055848.PMID 14593080.S2CID 8036750.
^Rizzi A, Gavioli EC, Marzola G, Spagnolo B, Zucchini S, Ciccocioppo R, et al. (June 2007). "Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies".The Journal of Pharmacology and Experimental Therapeutics.321 (3):968–74.doi:10.1124/jpet.106.116780.PMID 17329551.S2CID 2557475.